

FOR IMMEDIATE DISTRIBUTION

CONTACT:

Hon. Julian Byng
Natural-Immunogenics Corp. – U.K.
+44 (0) 1494-489-014
julianfbyng@talk21.com

Kay Mitchen
Natural-Immunogenics Corp.
+1-954-979-0885
kay@natural-immunogenics.com

**NATURAL-IMMUNOGENICS TO PROVE THE BIOAVAILABILITY OF SILVER
HYDROSOL, DEMONSTRATING ITS SAFETY AS A FOOD SUPPLEMENT TO EFSA**

LONDON, U.K., Dec. 18 – The European Food Safety Authority (EFSA) yesterday published their scientific statement on silver hydrosol as a food supplement. In that statement, EFSA explained that it was “unable to assess the safety of silver hydrosols for nutritional purposes as a source of silver in food supplements and the bioavailability of silver from this source.” The statement precedes a ruling anticipated next year that will either allow or prohibit the sale of silver hydrosol in the European market after December 2009. If the bioavailability and safety is proven to EFSA’s satisfaction, silver hydrosol will remain on the European market.

EFSA’s statement is not a final ruling, but concludes that the preliminary non-clinical evidence submitted is insufficient to prove bioavailability and safety. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 lists, in its Annex II, the vitamins and minerals authorized for use as food supplements. Silver hydrosol is listed in the Derogation List, which allows this mineral to be used as a food supplement if sufficient evidence proves that this mineral is fully safe for consumption, based on bioavailability data.

Natural-Immunogenics will meet the requirements presented in EFSA’s statement for its silver hydrosol product lines, Sovereign Silver® and Argentyn23®, through well-designed human clinical trials assessing bioavailability and safety. Those trials, to be conducted in the United States by a well-respected independent clinical research organization, will provide conclusive data on the bioavailability of these hydrosols during the second quarter of 2009. Based on its own internal research, Natural-Immunogenics anticipates that these trials will prove the bioavailability and safety of the products, satisfying EFSA’s mandate to perform comprehensive risk assessment on food supplements.

“Although case studies exist proving the efficacy and safety of silver hydrosols, as manufactured and presented to EFSA by Natural-Immunogenics, none so far provide the bioavailability data EFSA is seeking,” said Robert S. Bell, D.A. Hom., Vice President for Education at Natural-Immunogenics Corp. “We are fully confident, however, that the trials we have commissioned by one of the leading clinical research organizations in the United States will provide data that clearly demonstrates the safety and bioavailability of silver hydrosols, permitting them to remain available for European consumers, like their American counterparts. Silver hydrosols provide a safe alternative for immune support at a time when that support is more urgently needed than at any other time in world history.”

In the nine years that Natural Immunogenics’ products have been on the market, there has been no report of any toxicological or other adverse effect. Dosing guidelines remain safely below the oral daily reference dose (RfD) as determined by the United States Environmental Protection Agency (EPA-CASRN 7440-22-4). According to recent data provided by SPINS, its market-leading Sovereign Silver remains the #1 selling silver hydrosol.

For additional information, please visit www.natural-immunogenics.com.

About Natural-Immunogenics Corp.

Natural-Immunogenics Corp. is the pioneer in the field of silver hydrosol technology and the leading manufacturer of safe and effective products in the colloidal silver category. Sovereign Silver, the company's core product, is the #1 selling silver hydrosol, and its professional brand, Argentyn23, is trusted by thousands of doctors around the world.

###